Biovail Sues Andrx Over Planned Cardizem Generic

Law360, New York (August 16, 2005, 12:00 AM EDT) -- A popular drug for controlling blood pressure is at the center of a new patent lawsuit brought by Biovail Laboratories against generics maker Andrx Pharmaceuticals.

Biovail, based in Barbados, sued Florida-based Andrx in Delaware district court. It asserted a patent that reshaped the hypertension drug niche in the mid-1990s.

Andrx completed an Abbreviated New Drug Application with the Food and Drug Administration, stating its intentions to create and market a generic version of Biovail’s Cardizem LA. Compelled by the Hatch-Waxman Act, Andrx informed Biovail of its...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.